19-03.1-09. Schedule III

19-03.1-09. Schedule III

1. The controlled substances listed in this section are included in schedule III.

2. Schedule III consists of the drugs and other substances, by whatever official name,

common or usual name, chemical name, or brand name designated, listed in this

section.

3. Stimulants. Unless specifically excepted or unless listed in another schedule, any

material, compound, mixture, or preparation which contains any quantity of the

following substances having a stimulant effect on the central nervous system, including

its salts, isomers (whether optical, position, or geometric), and salts of such isomers

whenever the existence of such salts, isomers, and salts of isomers is possible within

the specific chemical designation:

a. Those compounds, mixtures, or preparations in dosage unit form containing any

stimulant substances listed in schedule II and any other drug of the quantitative

composition shown in that schedule for those drugs or which is the same except

that it contains a lesser quantity of controlled substances.

b. Benzphetamine.

c. Chlorphentermine.

d. Clortermine.

e. Phendimetrazine.

4. Depressants. Unless specifically excepted or unless listed in another schedule, any

material, compound, mixture, or preparation that contains any quantity of the following

substances having a depressant effect on the central nervous system:

a. Any compound, mixture, or preparation containing:

(1) Amobarbital;

(2) Secobarbital;

(3) Pentobarbital;

or any salt thereof and one or more other active medicinal ingredients which are

not listed in any schedule.

b. Any suppository dosage form containing:

(1) Amobarbital;

(2) Secobarbital;

(3) Pentobarbital;

or any salt of any of these drugs and approved by the food and drug

administration for marketing only as a suppository.

c. Any substance that contains any quantity of a derivative of barbituric acid, or any

salt of a derivative of barbituric acid, except those substances which are

specifically listed in other schedules thereof.

d. Chlorhexadol.

e. Embutramide.

f. Gamma-hydroxybutyric acid in a United States food and drug administration-

approved drug product.

g. Ketamine.

h. Lysergic acid.

i. Lysergic acid amide.

j. Methyprylon.

k. Perampanel.

l. Sativex or its successor name as determined by the federal food and drug

administration.

m. Sulfondiethylmethane.

n. Sulfonethylmethane.

o. Sulfonmethane.

p. Tiletamine and zolazepam or any salt thereof. Some trade or other names for a

tiletamine-zolazepam combination product: Telazol. Some trade or other names

for tiletamine: 2-(ethylamino)-2-(2-thienyl)-cyclohexanone. Some trade or other

names for zolazepam: 4-2(2-fluorophenyl)-6, 8-dihydro-1,3,8-trimethylpyrazolo-

[3,4-e][1,4]-diazepin-7(1H)-one, flupyrazapon.

5. Nalorphine.

6. Narcotic drugs. Unless specifically excepted or unless listed in another schedule, any

material, compound, mixture, or preparation that contains any of the following narcotic

drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited

quantities as set forth below:

a. (1) Not more than 1.80 grams of codeine per 100 milliliters or not more than

90 milligrams per dosage unit, with an equal or greater quantity of an

isoquinoline alkaloid of opium.

(2) Not more than 1.80 grams of codeine per 100 milliliters or not more than

90 milligrams per dosage unit, with one or more active, non-narcotic

ingredients in recognized therapeutic amounts.

(3) Not more than 1.80 grams of dihydrocodeine per 100 milliliters or not more

than 90 milligrams per dosage unit, with one or more active, non-narcotic

ingredients in recognized therapeutic amounts.

(4) Not more than 300 milligrams of ethylmorphine per 100 milliliters or not

more than 15 milligrams per dosage unit, with one or more active,

non-narcotic ingredients in recognized therapeutic amounts.

more than 1.80 grams of dihydrocodeine per 100 milliliters or not more

than 90 milligrams per dosage unit, with one or more active, non-narcotic

ingredients in recognized therapeutic amounts.

(4) Not more than 300 milligrams of ethylmorphine per 100 milliliters or not

more than 15 milligrams per dosage unit, with one or more active,

non-narcotic ingredients in recognized therapeutic amounts.

(5) Not more than 500 milligrams of opium per 100 milliliters or per 100 grams,

or not more than 25 milligrams per dosage unit, with one or more active,

non-narcotic ingredients in recognized therapeutic amounts.

(6) Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams

with one or more active, non-narcotic ingredients in recognized therapeutic

amounts.

b. Buprenorphine.

7. Anabolic steroids. Unless specifically excepted or unless listed in another schedule,

any material, compound, mixture, or preparation that contains any quantity of the

following substances, including its salts, esters, and ethers:

a. 3beta,17-dihydroxy-5a-androstane;

b. 3alpha,17beta-dihydroxy-5a-androstane;

c. 5alpha-androstan-3,17-dione;

d. 5alpha-androstan-3,6,17-trione;

e. 1-androstenediol (3beta,17beta-dihydroxy-5alpha-androst-1-ene);

f. 1-androstenediol (3alpha,17beta-dihydroxy-5alpha-androst-1-ene);

g. 4-androstenediol (3beta,17beta-dihydroxyandrost-4-ene);

h. 5-androstenediol (3beta,17beta-dihydroxy-androst-5-ene);

i. 1-androstenedione ([5alpha]-androst-1-en-3,17-dione);

j. 4-androstenedione (androst-4-en-3,17-dione);

k. 5-androstenedione (androst-5-en-3,17-dione);

l. Bolasterone (7alpha,17alpha-dimethyl-17beta-hydroxyandrost-4-en-3-one);

m. Boldenone (17beta-hydroxyandrost-1,4,-diene-3-one);

n. Boldione (androsta-1,4-diene-3,17-dione);

o. 6-bromo-androsta-1,4-diene-3,17-dione;

p. 6-bromo-androstan-3,17-dione;

q. Calusterone (7beta,17alpha-dimethyl-17beta-hydroxyandrost-4-en-3-one);

r. 4-chloro-17alpha-methyl-androsta-1,4-diene-3,17beta-diol;

s. 4-chloro-17alpha-methyl-androst-4-ene-3beta,17beta-diol;

t. 4-chloro-17alpha-methyl-17beta-hydroxy-androst-4-en-3-one;

u. 4-chloro-17alpha-methyl-17beta-hydroxy-androst-4-ene-3,11-dione;

v. Clostebol (4-chloro-17beta-hydroxyandrost-4-en-3-one);

w. Dehydrochloromethyltestosterone (4-chloro-17beta-hydroxy-17alpha-methyl-

androst-1,4-dien-3-one);

x. Delta-1-dihydrotestosterone (also known as '1-testosterone') (17beta-hydroxy-

5alpha-androst-1-en-3-one);

y. Desoxymethyltestosterone (17a-methyl-5a-androst-2-en-17beta-ol) (also known

as madol);

z. 4-dihydrotestosterone (17beta-hydroxy-androstan-3-one);

aa. 3beta,17beta-dihydroxy-5alpha-androstane;

bb. 3alpha,17beta-dihydroxy-5alpha-androstane;

cc. 2alpha,17alpha-dimethyl-17beta-hydroxy-5beta-androstan-3-one;

dd. Drostanolone (17beta-hydroxy-2alpha-methyl-5alpha-androstan-3-one);

ee. 2alpha,3alpha-epithio-17alpha-methyl-5alpha-androstan-17beta-ol;

ff. estra-4,9,11-triene-3,17-dione;

gg. 13beta-ethyl-17beta-hydroxygon-4-en-3-one;

hh. Ethylestrenol (17alpha-ethyl-17beta-hydroxyestr-4-ene);

ii. Fluoxymesterone (9-fluoro-17alpha-methyl-11beta, 17beta-dihydroxyandrost-4-

en-3-one);

jj. Formebolone (2-formyl-17alpha-methyl-11alpha, 17beta-dihydroxyandrost-1,4-

dien-3-one);

kk. Furazabol (17alpha-methyl-17beta-hydroxyandrostano[2,3-c]-furazan);

ll. [3,2-c]furazan-5alpha-androstan-17beta-ol;

mm. 18a-homo-3-hydroxy-estra-2,5(10)-dien-17-one;

nn. 4-hydroxy-androst-4-ene-3,17-dione;

oo. 17beta-hydroxy-androstano[2,3-d]isoxazole;

pp. 17beta-hydroxy-androstano[3,2-c]isoxazole;

qq. 3beta-hydroxy-estra-4,9,11-trien-17-one;

rr. 13beta-ethyl-17alpha-hydroxygon-4-en-3-one;

ss. 4-hydroxytestosterone (4,17beta-dihydroxy-androst-4-en-3-one);

tt. 4-hydroxy-19-nortestosterone (4,17beta-dihydroxy-estr-4-en-3-one);

uu. Mestanolone (17alpha-methyl-17beta-hydroxy-5alpha-androstan-3-one);

vv. Mesterolone (1alpha-methyl-17beta-hydroxy-[5alpha]-androstan-3-one);

o[3,2-c]isoxazole;

qq. 3beta-hydroxy-estra-4,9,11-trien-17-one;

rr. 13beta-ethyl-17alpha-hydroxygon-4-en-3-one;

ss. 4-hydroxytestosterone (4,17beta-dihydroxy-androst-4-en-3-one);

tt. 4-hydroxy-19-nortestosterone (4,17beta-dihydroxy-estr-4-en-3-one);

uu. Mestanolone (17alpha-methyl-17beta-hydroxy-5alpha-androstan-3-one);

vv. Mesterolone (1alpha-methyl-17beta-hydroxy-[5alpha]-androstan-3-one);

ww. Methandienone (17alpha-methyl-17beta-dihydroxyandrost-1,4-dien-3-one);

xx. Methandriol (17alpha-methyl-3beta,17beta-dihydroxyandrost-5-ene);

yy. Methasterone (2[alpha],17[alpha]-dimethyl-5[alpha]-androstan-17[beta]-ol-3-one);

zz. Methenolone (1-methyl-17beta-hydroxy-5alpha-androst-1-en-3-one);

aaa. 17alpha-methyl-androsta-1,4-diene-3,17beta-diol;

bbb. 17alpha-methyl-5alpha-androstan-17beta-ol;

ccc. 17alpha-methyl-androstan-3-hydroxyimine-17beta-ol;

ddd. 6alpha-methyl-androst-4-ene-3,17-dione;

eee. 17alpha-methyl-androst-2-ene-3,17beta-diol;

fff. 17alpha-methyl-3beta,17beta-dihydroxy-5a-androstane;

ggg. 17alpha-methyl-3alpha,17beta-dihydroxy-5a-androstane;

hhh. 17alpha-methyl-3beta,17beta-dihyroxyandrost-4-ene;

iii. 17alpha-methyl-4-hydroxynandrolone (17alpha-methyl-4-hydroxy-17beta-

hydroxyestr-4-en-3-one);

jjj. Methyldienolone (17alpha-methyl-17beta-hydroxyestra-4,9(10)-dien-3-one);

kkk. Methyltrienolone (17alpha-methyl-17beta-hydroxyestra-4,9(11)-trien-3-one);

lll. Methyltestosterone (17alpha-methyl-17beta-hydroxyandrost-4-en-3-one);

mmm. Mibolerone (7alpha,17alpha-dimethyl-17beta-hydroxyestr-4-en-3-one);

nnn. 17alpha-methyl-delta1-dihydrotestosterone (17bbeta-hydroxy-17alpha-methyl-

5alpha-androst-1-en-3-one) (also known as '17-alpha-methyl-1-testosterone');

ooo. Nandrolone (17beta-hydroxyestr-4-en-3-one);

ppp. 19-nor-4-androstenediol (3beta,17beta-dihydroxyestr-4-ene);

qqq. 19-nor-4-androstenediol (3alpha,17beta-dihydroxyestr-4-ene);

rrr. 19-nor-5-androstenediol (3beta,17beta-dihydroxyestr-5-ene);

sss. 19-nor-5-androstenediol (3alpha,17-beta-dihydroxyester-5-ene);

ttt. 19-nor-4-androstenedione (estr-4-en-3,17-dione);

uuu. 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-dione);

vvv. 19-nor-5-androstenedione (estr-5-en-3,17-dione);

www. Norboletheone (13beta,17alpha-diethyl-17beta-hydroxygon-4-en-3-one);

xxx. Norclostebol (4-chloro-17beta-hydroxyestr-4-en-3-one);

yyy. Norethandrolone (17alpha-ethyl-17beta-hydroxyestr-4-en-3-one);

zzz. Normethandrolone (17alpha-methyl-17beta-hydroxyestr-4-en-3-one);

aaaa. Oxandrolone (17alpha-methyl-17beta-hydroxy-2-oxa-[5alpha]-androstan-3-one);

bbbb. Oxymesterone (17alpha-methyl-4-17beta-dihydroxyandrost-4-en-3-one);

cccc. Oxymetholone (17alpha-methyl-2-hydroxymethylene-17beta-hydroxy [5alpha]-

androstan-3-one);

dddd. [3,2-c]pyrazole-androst-4-en-17beta-ol;

eeee. Stanozolol (17alpha-methyl-17beta-hydroxy[5alpha]-androst-2-eno[3,2-c]-

pyrazole);

ffff. Stenbolone (17beta-hydroxy-2-methyl-[5alpha]-androst-1-en-3-one);

gggg. Prostanozol (17[beta]- hydroxy-5[alpha]-androstano[3,2-c]pyrazole);

hhhh. Testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid

lactone);

iiii. Testosterone (17beta-hydroxyandrost-4-en-3-one);

jjjj. Tetrahydrogestrinone (13beta,17alpha-diethyl-17beta-hydroxygon-4,9,11-trien-3-

one); or

kkkk. Trenbolone (17beta-hydroxyestr-4,9,11-trien-3-one).

The term does not include an anabolic steroid that is expressly intended for

administration through implants to cattle or other nonhuman species and which has

been approved by the secretary of health and human services for administration

unless any person prescribes, dispenses, possesses, delivers, or distributes for

human use.

8. Hallucinogenic substances.

a. Dronabinol (synthetic) [(-)-delta-9-(trans)-tetrahydrocannabinol] in sesame oil and

encapsulated in a soft gelatin capsule in a United States food and drug

administration-approved drug product.

b. Any product in hard or soft gelatin capsule form containing natural dronabinol

any person prescribes, dispenses, possesses, delivers, or distributes for

human use.

8. Hallucinogenic substances.

a. Dronabinol (synthetic) [(-)-delta-9-(trans)-tetrahydrocannabinol] in sesame oil and

encapsulated in a soft gelatin capsule in a United States food and drug

administration-approved drug product.

b. Any product in hard or soft gelatin capsule form containing natural dronabinol

(derived from the cannabis plant) or synthetic dronabinol (produced from

synthetic materials) in sesame oil, for which an abbreviated new drug application

has been approved by the food and drug administration under section 505(j) of

the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 355(j)] which references as

its listed drug the drug product referred to in subdivision a.

9. The board may except by rule any compound, mixture, or preparation containing any

stimulant or depressant substance listed in subsections 3 and 4 from the application of

all or any part of this chapter if the compound, mixture, or preparation contains one or

more active medicinal ingredients not having a stimulant or depressant effect on the

central nervous system, and if the admixtures are included therein in combinations,

quantity, proportion, or concentration that vitiate the potential for abuse of the

substances which have a stimulant or depressant effect on the central nervous

system.